‘Ex Machina': The Consciousness Test

If only Alan Turing was alive today.

He would have enjoyed the acclaim of the movie about his life, The Imitation Game, and the great public interest around his role in helping to end WWII, the beginnings of the modern computer and the test for artificial intelligence that bears his name.

Turing would have been able to share the thrill, as Stephen Hawking did while still alive, in the making of the movie of his life, The Theory of Everything – a film that dramatically places Hawking in the pantheon of great modern theorists.

And he would have delighted in the artful and challenging, Ex Machina a movie set in the near future which uses the Turing Test as a starting point for an exploration of artificial intelligence and what it means to be human.

The movie title is taken from the Latin phrase, Deus ex machina or God out of the machine — a reference to a Greek theatrical device whereby a god is lowered on a mechanical crane to resolve a conflict or problem the clueless humans can’t solve. Interestingly, while removing the god from the title of the movie, man’s god-like ambitions are on full display in this modern day drama.

The action is set in a remote and wildly beautiful hideaway of Nathan, the fabulously wealthy founder of the world’s most dominant search engine, Blue Book. The fact that billionaire Larry Page, the co-founder of Google, describes his company as being in the business of AI or artificial intelligence is, perhaps, not entirely coincidental. The film opens with a Blue Book employee, Caleb, being flown out to his boss’s lair having “won” a chance to spend a week with the great man.

Caleb quickly learns that he is actually there —> Read More

Penn Medicine: Immunotherapy drug pembrolizumab shows promise for mesothelioma patients

The PD-1 inhibitor pembrolizumab, a cancer immunotherapy drug, shrank or halted growth of tumors in 76 percent of patients with pleural mesothelioma, a rare and deadly form of cancer that arises in the outer lining of the lungs and internal chest wall, according to a new study from researchers in the Perelman School of Medicine at the University of Pennsylvania. —> Read More

Investigational personalized cellular therapy tolerated well by patients

Genetically modified versions of patients’ own immune cells successfully traveled to tumors they were designed to attack in an early-stage trial for mesothelioma and pancreatic and ovarian cancers at the Perelman School of Medicine at the University of Pennsylvania. The data adds to a growing body of research showing the promise of CAR T cell technology. The interim results will be presented at the American Association for Cancer Research Annual Meeting 2015, April 18-22. —> Read More

1 2 3 2,545